IL-22 Novel Inflammatory Cytokine Marker


Interleukin-22 (IL-22) has shown high clinical relevance in offering efficacy assessment as a novel target in an array of disorders associated with chronic inflammatory diseases of the skin, intestines, lungs and joints and well as chronic infections such as hepatitis, pancreatitis and cancer.


Randox Laboratories have developed a highly sensitive IL-22 assay which is analytically verified and available for use across clinical trials to measure IL-22 variations from baseline in response to compound activity. Accumulative research and results have strongly suggested that the inhibition of IL-22 activity may be beneficial in several diseases / disorders to establish adverse effects associated with therapies and interventions.


• Highly sensitive LOQ from 0.1 pg/ml (Biochip 4 plex) to 1.4 pg/ml • Established assay range from 1.4 to 100 pg/ml (automated platform) • No significant interference • Control & Calibrator material available


Epidermal Keratinocytes


Intestinal Epithelial Cells


IL-22 Respiratory Epithelial Cells Hepatocytes


Synovial Fibroblasts


Pancreatic Cells


+44 (0) 28 9442 2413 | randox.com | marketing@randox.com


Copyright © 2021 Randox Laboratories Ltd. All rights Reserved. VAT number: GB 151682708. Product availability may vary from country to country. Some products may be for Research Use Only. For more information on product application and availability, please contact your local Randox Representative


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45